scholarly journals Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country

2020 ◽  
Vol 67 (9) ◽  
Author(s):  
Frederick W. Thielen ◽  
Maite E. Houwing ◽  
Marjon H. Cnossen ◽  
Ilona A. al Hadithy‐Irgiztseva ◽  
Jan A. Hazelzet ◽  
...  
2009 ◽  
Vol 84 (6) ◽  
pp. 323-327 ◽  
Author(s):  
Teresa L. Kauf ◽  
Thomas D. Coates ◽  
Liu Huazhi ◽  
Nikita Mody-Patel ◽  
Abraham G. Hartzema

2019 ◽  
Vol 111 (1) ◽  
pp. 54-61 ◽  
Author(s):  
Monica Ter-Minassian ◽  
Sophie Lanzkron ◽  
Alphonse Derus ◽  
Elizabeth Brown ◽  
Michael A. Horberg

2020 ◽  
Author(s):  
Jacquelyn Baskin ◽  
Anne Nord ◽  
Dawn Canada ◽  
Kelly Russell ◽  
Payal Shah ◽  
...  

2020 ◽  
Vol 4 (16) ◽  
pp. 3814-3821 ◽  
Author(s):  
Susanna A. Curtis ◽  
Dana Lew ◽  
Jonathan Spodick ◽  
Jeanne E. Hendrickson ◽  
Caterina P. Minniti ◽  
...  

Abstract More than one-third of adults with sickle cell disease (SCD) report using cannabis-based products. Many states list SCD or pain as qualifying conditions for medical marijuana, but there are few data to guide practitioners whether or whom should be certified. We postulated that certifying SCD patients may lead to a reduction in opioid use and/or health care utilization. Furthermore, we sought to identify clinical characteristics of patients who would request this intervention. Retrospective data obtained over the study period included rates of health care and opioid utilization for 6 months before certification and after certification. Patients who were certified but failed to obtain medical marijuana were compared with those who obtained it. Patients who were certified were invited to participate in a survey regarding their reasons for and thoughts on certification. Patients who were certified for medical marijuana were compared with 25 random patients who did not request certification. Fifty adults with SCD were certified for medical marijuana and 29 obtained it. Patients who obtained medical marijuana experienced a decrease in admission rates compared with those who did not and increased use of edible cannabis products. Neither group had changes in opioid use. Patients who were certified for medical marijuana had higher rates of baseline opioid use and illicit cannabis use compared with those who did not request certification. Most patients with SCD who requested medical marijuana were already using cannabis illicitly. Obtaining medical marijuana decreased inpatient hospitalizations.


2020 ◽  
Vol 105 (9) ◽  
pp. e11.1-e11
Author(s):  
Masuma Dhanji

AimTo assess the prescribing of analgesia to manage pain crises in children with SCD. This was to establish whether the Trust was meeting national and local standards. Prompt pain control is essential to reduce length of stay and further complications.1Standards100% of admissions will be prescribed regular paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) at the recommended frequency unless contraindicated in accordance with national guidance.2 3100% of admissions will be prescribed appropriate doses of analgesia with consideration to weight and age in accordance with local policy.4MethodThe audit was registered with the Trust’s audit committee. A list of paediatric patients with the diagnosis of SCD was sought from paediatricians with an interest in haematology. A data collection form was created. Data was collected retrospectively over a one-year period. A total of 60 admissions were reviewed to check whether analgesia was prescribed regularly at the recommended frequency, and at the correct dose. Results were analysed using descriptive statistical analysis. Exclusion criteria included patients with hospital admissions under 24 hours.ResultsA total of 55 admissions were included in the final sample. The audit showed the Trust was non-adherent to both standards assessed. A total of 45% (95% CI [31.9%, 58.1%]) of admissions were prescribed regular analgesia. A total of 78% (95% CI [67.9%, 88.9%] of admissions were prescribed appropriate doses of analgesia. Two main reasons were found as to why analgesia was prescribed at the incorrect dose. This was due to incorrect weights recorded on the electronic system (n=4) and doses based on age only (n=8).ConclusionThe results show prescribers are familiar with the correct doses of analgesia but fail to prescribe analgesia regularly. This highlights an opportunity for education and training in the management of pain crisis in SCD. One recommendation includes development of an integrated care pathway booklet for paediatric patients presenting with pain crisis due to SCD. Integrated care pathway booklets have been implemented for other conditions such as cystic fibrosis yielding positive outcomes. The results have highlighted key issues surrounding the electronic prescribing system such as out-of-date weights remaining on the system unless updated, and default treatment protocols. The electronic prescribing system requires refinement for use within paediatrics. One suggestion includes compulsory weight field on admission. Limitations of this audit included small sample size. There was a lack of data to make suggestions based on different ages.ReferencesRees D, Olujohungbe A, Parker N, et al. Guidelines for the management of the acute painful crises in sickle cell disease. Br J Haemato 2003;120:744–752.National Institute for Health and Care Excellence (2012) Sickle cell disease: managing acute painful episodes in hospital. NICE Guideline (CG143).Paediatric Formulary Committee. BNF for Children (2018–2019). London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; (2018).General Hospital (2015) Management of sickle cell disease in paediatric patients (CG377).


2020 ◽  
Vol 99 (7) ◽  
pp. 1465-1474 ◽  
Author(s):  
Marina García-Morín ◽  
Eduardo J. Bardón-Cancho ◽  
Cristina Beléndez ◽  
Rosario Zamarro ◽  
Cristina Béliz-Mendiola ◽  
...  

2014 ◽  
Vol 15 (4) ◽  
pp. S37 ◽  
Author(s):  
V. Mathur ◽  
C. Haywood ◽  
S. Bediako ◽  
R. Edwards ◽  
C. Campbell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document